Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Operating Leases (2020 - 2025)

SAB Biotherapeutics' Operating Leases history spans 6 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 223.04% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, up 223.04%, while the annual FY2025 figure was $1.9 million, 223.04% up from the prior year.
  • Operating Leases reached $1.9 million in Q4 2025 per SABSW's latest filing, down from $2.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.5 million in Q1 2025 to a low of $91816.0 in Q2 2023.
  • Average Operating Leases over 5 years is $1.1 million, with a median of $772605.0 recorded in 2022.
  • Peak YoY movement for Operating Leases: plummeted 91.35% in 2023, then surged 752.18% in 2024.
  • A 5-year view of Operating Leases shows it stood at $1.7 million in 2021, then crashed by 78.15% to $361225.0 in 2022, then soared by 76.01% to $635777.0 in 2023, then decreased by 8.59% to $581148.0 in 2024, then soared by 223.04% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Operating Leases are $1.9 million (Q4 2025), $2.0 million (Q3 2025), and $2.3 million (Q2 2025).